RBC Capital raised the firm’s price target on Regeneron to $1,184 from $1,096 and keeps an Outperform rating on the shares. The company’s Dupixent continues on its impressive growth trajectory with sales guidance this year indicating potential above-20% y/y growth and deeper entrenchment in existing indications, along with additional label expansion opportunities that should maintain the program as a key value driver for Regeneron in the long term, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
- Regeneron sees FY24 adjusted EPS $1.42-$1.49, consensus $1.77
- Regeneron announces U.S. FDA accepted priority review for BLA for linvoseltamab
- Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
